Aeterna Zentaris to Announce Second Quarter 2018 Financial and Operating Results on August 9, 2018

CHARLESTON, S.C., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. AEZS AEZS will announce its second quarter 2018 financial and operating results after market close on Thursday, August 9, 2018. The Company will host a conference call to discuss these results on Friday, August 10, 2018 at 8:30 a.m. Eastern Time.

Participants may access the conference call by telephone using the following numbers:

• Toll-Free: 877-407-8029, Confirmation #13681858
• Toll: 201-689-8029, Confirmation #13681858

A replay will also be available on the Company's website for a period of 30 days.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a specialty biopharmaceutical company focused on developing and commercializing, principally through out-licensing arrangements, Macrilen™ (macimorelin), an oral ghrelin receptor agonist, to be administered in the diagnosis of patients with adult growth hormone deficiency.  Aeterna Zentaris has entered into a license and assignment agreement with a wholly-owned subsidiary of Strongbridge Biopharma plc to carry out development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the United States and Canada. For more information, visit www.zentaris.com.

Contact:

Aeterna Zentaris Inc.

James Clavijo

Chief Financial Officer

IR@aezsinc.com

843-900-3201